About us
Organon & Co : a strong commitment to women’s health
Organon & Co is dedicated to improving women’s health by addressing conditions that uniquely affect them, disproportionately impact them, or impact them differently. Operating in over 140 countries, this commitment is rooted in a strong European industrial legacy, which accounts for 50% of its manufacturing footprint. Supported by a global network of approximately 10,000 founders, Organon drives change to prioritize women’s health, uphold responsible business practices, and foster an inclusive community where everyone feels they belong.
Women’s health at the core of our engagement
Organon has a rich legacy of commitment to women’s health, tracing back to its founding in the Netherlands in 1923. At the core of this dedication lies innovation, driving efforts to expand its portfolio in key areas such as contraception, menopause, endometriosis, and maternal health. The company also focuses on addressing diseases that disproportionately or uniquely impact women.
- Acquisition of Alydia, in March 2021, to develop a medical device to prevent morbidity and mortality in women during childbirth.
- Acquisition of Forendo Pharma, in November 2021, to develop a treatment of endometriosis and polycystic ovarian syndrome (PCOS).
- Partnership with Daré Bioscience, in March 2022, to market a treatment for women and girls aged 12 and older with bacterial vaginosis.
- An agreement with Henlius Biotech, in June 2022, to expand the portfolio of biosimilars for use by certain breast cancer patients, and by osteoporosis patients with a high risk of fracture. The agreement does not include China or its territories.
- An agreement with Cirqle, in July 2022, to collaborate around the research of a new non-hormonal contraceptive.
- An agreement with Claria Medical, Inc., in January 2023, to develop a medical device aimed at improving the laparoscopic hysterectomy procedure.
- Partnership with Lilly, in December 2023, to market a migraine prevention treatment.
A strong manufacturing footprint
The company has a large industrial footprint with 50% of its manufacturing sites in Europe (Netherlands, Belgium, Great-Britain)
6 industrial sites with top-tier capabilities
Our vision, our reason for being, and our mission
A better and healthier every day for everywoman
BE-NON-110157 – June 2025